Effects of magnesium citrate, magnesium oxide and magnesium sulfate on arterial stiffness 145 6 Magnesium citrate (n=46) Magnesium oxide (n=46) Magnesium sulfate (n=46) Placebo (n=26) 12-wk Median 74 (66-86) 77 (67-88) 72 (65-84) 0.97 ± 0.15 Difference vs placebo -0.0 (-0.0; 0.0) -0.01 (-0.03; 0.01) -0.01 (-0.02; 0.01) .. 24-wk Median 74 (65-83) 76 (63-87) 72 (64-81) 0.99 ± 0.14 Difference vs placebo -0.0 (-0.0; 0.0) -0.00 (-0.02; 0.01) -0.00 (-0.03; 0.01) .. Values are mean ± SD or median (interquartile range). Adjusted mean differences (95% CIs and) were obtained from linear mixed-effect models with age, sex, baseline value of the outcome of interest, time, intervention, and the interaction time × intervention as fixed effects. * P < 0.05 (two-sided P values). Supplemental Table 3. Effects of magnesium citrate, magnesium oxide and magnesium sulfate (vs placebo) on urinary minerals. Magnesium citrate (n=46) Magnesium oxide (n=46) Magnesium sulfate (n=46) Placebo (n=26) Urinary calcium 2-wk Mean, mmol/24-h 4.9 ± 2.2 6.0 ± 2.7 5.4 ± 2.4 4.5 ± 2.1 Difference vs placebo 0.5 (-0.3; 1.4) 1.0 (0.1; 1.9)* 0.7 (-0.1; 1.6) .. 12-wk Mean, mmol/24-h 5.0 ± 2.2 5.8 ± 2.8 5.3 ± 2.3 4.1 ± 1.7 Difference vs placebo 1.0 (0.1; 1.9)* 1.2 (0.4; 2.1)** 1.0 (0.1; 1.9)* .. 24-wk Mean, mmol/24-h 4.8 ± 2.3 5.9 ± 2.8 5.3 ± 2.7 4.1 ± 1.5 Difference vs placebo 0.8 (-0.0; 1.7) 1.2 (0.4; 2.1)** 1.0 (0.1; 1.8)* .. Urinary potassium 2-wk Mean, mmol/24-h 87.3 ± 25.0 97.3 ± 28.1 93.2 ± 24.6 80.4 ± 29.3 Difference vs placebo 13.0 (0.4; 25.6)* 17.4 (4.8; 29.9)** 15.8 (3.3; 28.2)* .. 12-wk Mean, mmol/24-h 88.9 ± 25.3 98.0 ± 29.2 95.2 ± 32.4 81.2 ± 24.6 Difference vs placebo 11.7 (-0.9; 24.4) 16.4 (3.8; 28.9)* 14.8 (2.2; 27.3)* .. 24-wk Mean, mmol/24-h 90.2 ± 26.3 95.5 ± 27.6 94.9 ± 31.4 79.7 ± 28.9 Difference vs placebo 15.1 (2.4; 27.9)* 15.4 (2.8; 28.1)* 17.0 (4.4; 29.7)** .. Urinary sodium 2-wk Mean, mmol/24-h 143.3 ± 53.1 151.8 ± 55.7 154.3 ± 66.5 138.3 ± 45.9 Difference vs placebo 19.3 (-6.7; 45.2) 26.6 (0.7; 52.5)* 22.4 (-3.2; 47.9) .. Supplemental Table 2. (Continued)
RkJQdWJsaXNoZXIy MTk4NDMw